Nivolumab Plus Weekly Carboplatin and Paclitaxel as Induction in Resectable Locally Advanced Head and Neck Cancer
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2019
Price : $35 *
At a glance
- Drugs Carboplatin (Primary) ; Nivolumab (Primary) ; Paclitaxel (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 04 Dec 2019 Status changed from suspended to recruiting.
- 27 Nov 2019 Status changed from recruiting to suspended.
- 31 Aug 2018 Biomarkers information updated